Reports Document FDA Review Delays: What Drugmakers Should Know Now
FDA Law Blog: Drug Discovery
APRIL 21, 2025
By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process.
Let's personalize your content